These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19608674)

  • 1. Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene.
    Nurden P; Nurden AT; La Marca S; Punzo M; Baronciani L; Federici AB
    Haematologica; 2009 Nov; 94(11):1627-9. PubMed ID: 19608674
    [No Abstract]   [Full Text] [Related]  

  • 2. Von Willebrand's disease and the mechanisms of platelet function.
    Ruggeri ZM
    Ciba Found Symp; 1995; 189():35-45; discussion 45-50, 77-8. PubMed ID: 7587636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of thrombocytopenia in platelet-type von Willebrand disease.
    Bury L; Malara A; Momi S; Petito E; Balduini A; Gresele P
    Haematologica; 2019 Jul; 104(7):1473-1481. PubMed ID: 30655369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.
    Slayton WB; Patel M; Sola-Visner M; Harris N; Rivers A; Montgomery RR; Friedman KD
    J Pediatr Hematol Oncol; 2008 Sep; 30(9):708-11. PubMed ID: 18776767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors.
    Mancuso DJ; Tuley EA; Castillo R; de Bosch N; Mannucci PM; Sadler JE
    Thromb Haemost; 1994 Aug; 72(2):180-5. PubMed ID: 7831648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.
    Ngo KY; Glotz VT; Koziol JA; Lynch DC; Gitschier J; Ranieri P; Ciavarella N; Ruggeri ZM; Zimmerman TS
    Proc Natl Acad Sci U S A; 1988 Apr; 85(8):2753-7. PubMed ID: 3258663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development.
    Surdhar GK; Enayat MS; Lawson S; Williams MD; Hill FG
    Blood; 2001 Jul; 98(1):248-50. PubMed ID: 11439975
    [No Abstract]   [Full Text] [Related]  

  • 9. Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation.
    Castaman G; Eikenboom JC; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 2000 Jan; 108(1):188-90. PubMed ID: 10651743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration of mRNA for von Willebrand factor in platelets of type I von Willebrand disease.
    Takenaka T; Kuribayashi K; Tsukiyama M; Nakamine H; Fukuhara Y; Kuno T
    Clin Chim Acta; 1996 Feb; 245(1):125-7. PubMed ID: 8646811
    [No Abstract]   [Full Text] [Related]  

  • 11. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation.
    Jackson SC; Sinclair GD; Cloutier S; Duan Z; Rand ML; Poon MC
    Blood; 2009 Apr; 113(14):3348-51. PubMed ID: 19060241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of gene mutation and genetic analysis of a patient with type 3 von Willebrand disease].
    Li Z; Wang Y; Wan H
    Zhonghua Xue Ye Xue Za Zhi; 1998 Mar; 19(3):122-4. PubMed ID: 11243141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.
    Gaucher C; Diéval J; Mazurier C
    Blood; 1994 Aug; 84(4):1024-30. PubMed ID: 8049421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New families with von Willebrand disease type 2M (Vicenza).
    Zieger B; Budde U; Jessat U; Zimmermann R; Simon M; Kätzel R; Sutor AH
    Thromb Res; 1997 Jul; 87(1):57-64. PubMed ID: 9253800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
    Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
    Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Von Willebrand factor and Von Willebrand disease].
    Verhezen PW; Beckers EA; Henskens YM
    Ned Tijdschr Geneeskd; 2014; 158():A6885. PubMed ID: 24800797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease.
    Gallinaro L; Sartorello F; Pontara E; Cattini MG; Bertomoro A; Bartoloni L; Pagnan A; Casonato A
    Thromb Haemost; 2006 Dec; 96(6):711-6. PubMed ID: 17139363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation.
    Casari C; Pinotti M; Lancellotti S; Adinolfi E; Casonato A; De Cristofaro R; Bernardi F
    Blood; 2010 Dec; 116(24):5371-6. PubMed ID: 20570857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.